Home > Dermatology > PFGC 2021 > Genes in Psoriasis and Psoriatic Arthritis > Protective factors identified against anti-drug antibody formation to adalimumab in psoriasis

Protective factors identified against anti-drug antibody formation to adalimumab in psoriasis

Presented By
Dr Teresa Tsakok, King’s College London, UK

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
PFGC 2021
The development of anti-drug antibodies (ADA) against adalimumab is an important cause of treatment failure in patients with psoriasis. In a genome-wide association study, certain amino acid variations within the human leukocyte antigens (HLA)-DR peptide-binding groove showed to be protective against ADA formation. Thus, pre-treatment HLA-DRB1 genotyping might be a promising option for patient selection. An analysis of the BADBIR registry enrolling more than 50% of patients with psoriasis in the United Kingdom revealed that the major reason for stopping biologic therapy is ineffectiveness [1]. “We know that at least some of this ineffectiveness is driven by drug immunogenicity, the ability of therapeutic proteins to trigger the development of ADA,” Dr Teresa Tsakok (King’s College London, UK) explained. ADA drive drug ineffectiveness by reducing levels of a functional drug. In a UK cohort, 65% of patients developed ADA over 3 years. ADA-positive patients w...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on